insulin and glp-1 agonist combination Frontiers Current Insights, Advantages and Challenges
Description
Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.
Issue 42 of The Altascientist explores GLP-1 receptor agonist drug development, covering preclinical models, bioanalytical assays, clinical study design, and manufacturing
Starting Jan.1, 2026, Pennsylvania will limit GLP1 weightloss drugs under Medicaid threatening access for thousands of lowincome patients.
GLP-1s are medications that mimic a natural hormone in the body that helps to regulate blood sugar levels and appetite
